Current Clinical Trials

Clinical trials are critical to finding better ways to prevent, diagnose and treat brain tumors. We participate in many National Cancer Institute-supported trials, as well as new and promising drug company trials. All of this gives you access to treatments that are only available at a handful of hospitals. Learn more about clinical trials.

Clinical trials are not open to everyone. Each trial protocol (detailed plan) will generally specify the type of brain tumor under investigation, the age and general health of the individual who will participate in the trial, and other treatments that the person has already received.

Below is an incomplete listing of our clinical trials. If you have questions about any of these trials, or would like to find out what other trials may be available, please contact our Clinical Trials Office at 434.243.6669, or call David Schiff, M.D., at 434.982.4415. You may also call us toll free at 800.362.2203.

• Phase I/II Study of ZD6474 (ZactimaTM) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Newly-Diagnosed Glioblastoma ...
  UVa Health System seeks adults with Glioblastoma for research study. Glioblastoma multiforme (GBM) is a malignant brain tumor. The usual treatments are: surgery, radiation therapy and chemotherapy. Unfortunately, these tumors are resi ...
  Primary Investigator: Schiff David 
• Phase I/II Study of Vorinostat (Suberoylandilide Hydroxamic Acid [SAHA], Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
  This study will look at the survival rate of patients treated with an investigational medicine called vorinostat in combination with standard radiation treatment and the standard chemotherapeutic agent Temozolomide.
  Primary Investigator: Schiff David
  

• Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas ...
  UVA Health System seeks adults with Low Grade Glioma for research study. Approximately 2000 patients are diagnosed with a grade II (low-grade) glioma each year ...
  Primary Investigator: Schiff David 
• Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma
  

  Glioblastoma (GBM) is a malignancy accounting for 81% of all malignant brain tumors. Unfortunately, there is no cure for this disease and many people die within 12-15 months...
  Primary Investigator: Schiff David 

• Phase I/II Study of LBH589 and Bevacizumab in Patients with Recurrent High Grade Glioma
  This study seeks to evaluate the effectiveness of an investigative oral chemotherapy agent, Panobinostat, taken in addition to standard Bevacizumab treatment in patients who have experienced a recurrence of high-grade glioma after standard therapy.
  Primary Investigator: Schiff David
  

• Phase II Trial of Bevacizumab in Patients with Recurrent or Progressive Meningiomas
  UVA Health System seeks men and women, 18 and older, with meningioma, hemangioblastoma or hemangiopericytoma to participate in a clinical research study. Meningiomas are a type of brain tumor. The usual treatments include surgery and radiation therapy/radiosurgery.
  Primary Investigator: Schiff David